Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies [Yahoo! Finance]
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: Yahoo! Finance
Shouryadeep "Deep" Srivastava, MD, PhD, joins Actym as Senior Vice President of Clinical Development, leading Actym's clinical activities BERKELEY, Calif. June 25, 2024 /PRNewswire/ -- Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointments of Mary J. Janatpour , PhD, as Chief Scientific Officer and Shouryadeep "Deep" Srivastava, MD, PhD, as Senior Vice President of Clinical Development. Drs. Janatpour and Srivastava bring extensive therapeutic product discovery and development expertise as Actym continues the clinical advancement of its lead program and expands its portfolio of drug candidates. In May, Actym announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to start a Phase 1 clinical trial of lead drug candidate ACTM-838. "We are fortunate to attract exceptional individuals with the depth of experience and skills that Mary and Deep bring to the company," said Tom
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- Catalent, Inc. (NYSE: CTLT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Catalent, Inc. (NYSE: CTLT) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.MarketBeat
- Catalent cut to neutral at Baird as analyst unable to find valuation in a deal break [Seeking Alpha]Seeking Alpha
- Catalent, Inc. (NYSE: CTLT) had its "neutral" rating re-affirmed by analysts at Robert W. Baird. They now have a $63.50 price target on the stock.MarketBeat
- Asia-Pacific CDMO Market Share Analysis, Industry Trends & Growth Forecasts 2024-2029: Demand For Injectable Dose Formulation is Rising in the Market [Yahoo! Finance]Yahoo! Finance
CTLT
Earnings
- 8/29/24 - Miss
CTLT
Sec Filings
- 9/27/24 - Form 4
- 9/26/24 - Form 144
- 9/6/24 - Form 10-K
- CTLT's page on the SEC website